These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 15713724)

  • 1. Oral testosterone in oil plus dutasteride in men: a pharmacokinetic study.
    Amory JK; Bremner WJ
    J Clin Endocrinol Metab; 2005 May; 90(5):2610-7. PubMed ID: 15713724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral testosterone in oil: pharmacokinetic effects of 5alpha reduction by finasteride or dutasteride and food intake in men.
    Amory JK; Page ST; Bremner WJ
    J Androl; 2006; 27(1):72-8. PubMed ID: 16400081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics, bioefficacy, and safety of sublingual testosterone cyclodextrin in hypogonadal men: comparison to testosterone enanthate--a clinical research center study.
    Salehian B; Wang C; Alexander G; Davidson T; McDonald V; Berman N; Dudley RE; Ziel F; Swerdloff RS
    J Clin Endocrinol Metab; 1995 Dec; 80(12):3567-75. PubMed ID: 8530600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism.
    Schubert M; Minnemann T; Hübler D; Rouskova D; Christoph A; Oettel M; Ernst M; Mellinger U; Krone W; Jockenhövel F
    J Clin Endocrinol Metab; 2004 Nov; 89(11):5429-34. PubMed ID: 15531493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Testosterone substitution normalizes elevated serum leptin levels in hypogonadal men.
    Jockenhövel F; Blum WF; Vogel E; Englaro P; Müller-Wieland D; Reinwein D; Rascher W; Krone W
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2510-3. PubMed ID: 9253326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of oral testosterone enanthate plus dutasteride for 4 weeks in normal men: implications for male hormonal contraception.
    Amory JK; Kalhorn TF; Page ST
    J Androl; 2008; 29(3):260-71. PubMed ID: 18046048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levonorgestrel implants (Norplant II) for male contraception clinical trials: combination with transdermal and injectable testosterone.
    Gonzalo IT; Swerdloff RS; Nelson AL; Clevenger B; Garcia R; Berman N; Wang C
    J Clin Endocrinol Metab; 2002 Aug; 87(8):3562-72. PubMed ID: 12161475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. III. Higher 5 alpha-reductase activity in oligozoospermic men administered supraphysiological doses of testosterone.
    Anderson RA; Wallace AM; Wu FC
    J Clin Endocrinol Metab; 1996 Mar; 81(3):902-8. PubMed ID: 8772548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel male hormonal contraceptive combinations: the hormonal and spermatogenic effects of testosterone and levonorgestrel combined with a 5alpha-reductase inhibitor or gonadotropin-releasing hormone antagonist.
    Matthiesson KL; Amory JK; Berger R; Ugoni A; McLachlan RI; Bremner WJ
    J Clin Endocrinol Metab; 2005 Jan; 90(1):91-7. PubMed ID: 15509637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Testosterone with dutasteride, but not anastrazole, improves insulin sensitivity in young obese men: a randomized controlled trial.
    Juang PS; Peng S; Allehmazedeh K; Shah A; Coviello AD; Herbst KL
    J Sex Med; 2014 Feb; 11(2):563-73. PubMed ID: 24344872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of testosterone and levonorgestrel combined with a 5alpha-reductase inhibitor or gonadotropin-releasing hormone antagonist on spermatogenesis and intratesticular steroid levels in normal men.
    Matthiesson KL; Stanton PG; O'Donnell L; Meachem SJ; Amory JK; Berger R; Bremner WJ; McLachlan RI
    J Clin Endocrinol Metab; 2005 Oct; 90(10):5647-55. PubMed ID: 16030154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanomilled oral testosterone plus dutasteride effectively normalizes serum testosterone in normal men with induced hypogonadism.
    Page ST; Bremner WJ; Clark RV; Bush MA; Zhi H; Caricofe RB; Smith PM; Amory JK
    J Androl; 2008; 29(2):222-7. PubMed ID: 18077826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. II. Pharmacokinetics and pharmacodynamics of once weekly administration of testosterone enanthate.
    Anderson RA; Wu FC
    J Clin Endocrinol Metab; 1996 Mar; 81(3):896-901. PubMed ID: 8772547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of testosterone undecanoate administered alone or in combination with letrozole or dutasteride in female to male transsexuals.
    Meriggiola MC; Armillotta F; Costantino A; Altieri P; Saad F; Kalhorn T; Perrone AM; Ghi T; Pelusi C; Pelusi G
    J Sex Med; 2008 Oct; 5(10):2442-53. PubMed ID: 18624972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sublingual administration of testosterone-hydroxypropyl-beta-cyclodextrin inclusion complex simulates episodic androgen release in hypogonadal men.
    Stuenkel CA; Dudley RE; Yen SS
    J Clin Endocrinol Metab; 1991 May; 72(5):1054-9. PubMed ID: 1902483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral testosterone undecanoate in the management of delayed puberty in boys: pharmacokinetics and effects on sexual maturation and growth.
    Butler GE; Sellar RE; Walker RF; Hendry M; Kelnar CJ; Wu FC
    J Clin Endocrinol Metab; 1992 Jul; 75(1):37-44. PubMed ID: 1619029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral testosterone with and without concomitant inhibition of 5α-reductase by dutasteride in hypogonadal men for 28 days.
    Amory JK; Bush MA; Zhi H; Caricofe RB; Matsumoto AM; Swerdloff RS; Wang C; Clark RV
    J Urol; 2011 Feb; 185(2):626-32. PubMed ID: 21168874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men.
    Zhang GY; Gu YQ; Wang XH; Cui YG; Bremner WJ
    J Androl; 1998; 19(6):761-8. PubMed ID: 9876028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative pharmacokinetics of three doses of percutaneous dihydrotestosterone gel in healthy elderly men--a clinical research center study.
    Wang C; Iranmanesh A; Berman N; McDonald V; Steiner B; Ziel F; Faulkner SM; Dudley RE; Veldhuis JD; Swerdloff RS
    J Clin Endocrinol Metab; 1998 Aug; 83(8):2749-57. PubMed ID: 9709942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in the apparent metabolic clearance rate of testosterone in young and older men with gonadotropin suppression receiving graded doses of testosterone.
    Coviello AD; Lakshman K; Mazer NA; Bhasin S
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4669-75. PubMed ID: 16912120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.